KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic) (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EPS (Basic) data on record, last reported at $8.2 in Q4 2025.

  • For Q4 2025, EPS (Basic) fell 3.98% year-over-year to $8.2; the TTM value through Dec 2025 reached $43.07, up 5.31%, while the annual FY2025 figure was $43.07, 5.31% up from the prior year.
  • EPS (Basic) reached $8.2 in Q4 2025 per REGN's latest filing, down from $14.09 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $29.51 in Q2 2021 and bottomed at $6.7 in Q1 2024.
  • Average EPS (Basic) over 5 years is $11.42, with a median of $10.58 recorded in 2021.
  • Peak YoY movement for EPS (Basic): surged 260.32% in 2021, then plummeted 73.23% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $15.37 in 2021, then dropped by 27.07% to $11.21 in 2022, then dropped by 2.85% to $10.89 in 2023, then fell by 21.58% to $8.54 in 2024, then dropped by 3.98% to $8.2 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $8.2 in Q4 2025, $14.09 in Q3 2025, and $13.2 in Q2 2025.